ERBB2 and gastric cancer: As part of the development of ICI combination therapy aimed at increasing the therapeutic effect of unresectable advanced gastric cancer, the KEYNOTE-811 study was conducted to evaluate the effect of adding pembrolizumab to trastuzumab + chemotherapy, which is the gold standard for HER2-positive gastric cancer.